Gilead shores up hope for NASH cocktail with a glimpse at positive proof-of-concept data

Gilead shores up hope for NASH cocktail with a glimpse at positive proof-of-concept data

Source: 
Endpoints
snippet: 

When Gilead conceded failure in its high-profile Phase III study for top late-stage NASH drug selonsertib, CSO John McHutchison pointed disappointed investors to a combination approach being tested in a mid-stage trial. Those data are not ready just yet, but today the big biotech unveiled some early numbers to bolster their case for a cocktail.